ESR1 and neoplasm: Although expression analysis of G-CSFR was not included in our study, we performed an exploratory analysis to address whether G-CSF expression contributed to prognostication in a subset of ER+ breast cancers with ≥10% TIL count (n = 284), and we observed no significant difference in survival between G-CSFhigh and G-CSFlow tumours (data not shown).